Company Description
electroCore, Inc., a bioelectronic medicine and general wellness company, provides non-invasive vagus nerve stimulation (“nVNS”) technology platform in the United States, the United Kingdom, and internationally.
The company develops gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania.
It also develops Truvaga 350, a personal use consumer electronics general wellness product and Truvaga Plus, an, app-enabled general wellness product.
It also offers non-invasive bioelectronic therapies for the treatment of chronic pain and wellness conditions.
In addition, the company offers TAC-STIM for human performance and gammaCore Sapphire, a portable, reusable, rechargeable, and reloadable prescription medical device for various primary headache conditions.
electroCore, Inc. was incorporated in 2005 and is headquartered in Rockaway, New Jersey.
| Country | United States |
| Founded | 2005 |
| IPO Date | Jun 22, 2018 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 73 |
| CEO | Daniel Goldberger |
Contact Details
Address: 200 Forge Way, Suite 205 Rockaway, New Jersey 07866 United States | |
| Phone | 973 290 0097 |
| Website | electrocore.com |
Stock Details
| Ticker Symbol | ECOR |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001560258 |
| CUSIP Number | 28531P103 |
| ISIN Number | US28531P2020 |
| Employer ID | 20-3454976 |
| SIC Code | 3845 |
Key Executives
| Name | Position |
|---|---|
| Daniel Goldberger | Chief Executive Officer |
| Joshua Lev | Chief Financial Officer |
| Manuel Marques | Chief Operating Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 24, 2025 | 424B3 | Prospectus |
| Oct 17, 2025 | D | Notice of Exempt Offering of Securities |
| Oct 17, 2025 | D | Notice of Exempt Offering of Securities |
| Oct 3, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| Oct 3, 2025 | 8-K | Current Report |
| Sep 16, 2025 | D | Notice of Exempt Offering of Securities |
| Sep 8, 2025 | SCHEDULE 13G | Filing |
| Sep 3, 2025 | 8-K | Current Report |
| Aug 6, 2025 | 10-Q | Quarterly Report |
| Aug 6, 2025 | 8-K | Current Report |